Breast cancer prognosis is steadily improving due to early detection of primary cancer in
screening programs and revolutionizing treatment development. In the metastatic setting …

Purpose The aim of this study was to compare fluorodeoxyglucose positron emission
tomography/computed tomography (FDG PET/CT) and contrast-enhanced computed …

This study aimed to compare CE-CT and 2-[18F] FDG-PET/CT for response monitoring
metastatic breast cancer (MBC). The primary objective was to predict progression-free and …

The PET Response Criteria in Solid Tumors (PERCIST) are not specific regarding the
number of lesions that should be analyzed per patient. This study evaluated how the number …

OBJECTIVE. FDG PET/CT affects the management of patients with breast cancer in multiple
settings, including initial staging, treatment response assessment, and evaluation of …

Background: We aimed to examine the feasibility and potential benefit of applying PET
Response Criteria in Solid Tumors (PERCIST) for response monitoring in metastatic breast …

Chemotherapy is currently the treatment of choice for patients with high-risk metastatic
breast cancer. Clinical response is determined after several cycles of chemotherapy by …

Increasing numbers of patients with newly diagnosed breast cancer receive primary
systemic therapy followed by surgery. Histopathology provides an accurate assessment of …

Fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT has shown promise for use in
assessing treatment response in patients with bone-only or bone-dominant (BD) metastatic …

Currently, the clinical role of positron emission tomography (PET) and PET/computed
tomography (CT) in patients with breast cancer is to provide additional information in select …